Načítá se...
Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis
The first approved Janus kinase (JAK) inhibitors for treatment of RA targeted more than one JAK molecule. Although this brings an advantage of simultaneous blocking of more cytokines involved in RA, it may also carry an increased risk of toxicity. Subsequently, more selective JAK inhibitors were dev...
Uloženo v:
| Vydáno v: | Rheumatology (Oxford) |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8098113/ https://ncbi.nlm.nih.gov/pubmed/33950228 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/keaa893 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|